{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:59:18Z","timestamp":1792180758575,"version":"4.4.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI11\/02004"],"award-info":[{"award-number":["PI11\/02004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0237739","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T17:37:01Z","timestamp":1597945021000},"page":"e0237739","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study"],"prefix":"10.1371","volume":"15","author":[{"given":"Silvana","family":"Di Yacovo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0047-1991","authenticated-orcid":true,"given":"Maria","family":"Saumoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"S\u00e1nchez-Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Sviridov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Javaloyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-1368","authenticated-orcid":true,"given":"Anton","family":"Vernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Pe\u00f1afiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ordo\u00f1ez-Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"pone.0237739.ref001","doi-asserted-by":"crossref","first-page":"e0176686","DOI":"10.1371\/journal.pone.0176686","article-title":"HIV infection as vascular risk: a systematic review of the literature.","volume":"12","author":"J Gutierrez","year":"2017","journal-title":"PLoS One."},{"key":"pone.0237739.ref002","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1093\/infdis\/jis195","article-title":"HIV infection and coronary heart disease: an intersection of epidemics","volume":"205","author":"VA Triant","year":"2012","journal-title":"J Infect Dis"},{"key":"pone.0237739.ref003","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/hiv.12257","article-title":"Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.","volume":"16","author":"S Hattab","year":"2015","journal-title":"HIV Medicine."},{"key":"pone.0237739.ref004","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","article-title":"Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s","volume":"61","author":"T Kelesidis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0237739.ref005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/cid\/ciw683","article-title":"Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection","volume":"64","author":"I Sereti","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0237739.ref006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"NI Wada","year":"2015","journal-title":"AIDS"},{"key":"pone.0237739.ref007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QAI.0000000000001320","article-title":"Changes in levels of inflammation after antiretroviral treatment during early HIV infection in AIDS Clinical Trials Group Study A5217.","volume":"75","author":"BJ Macatangay","year":"2017","journal-title":"J Acquir Immune Defic Syndr."},{"key":"pone.0237739.ref008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix082","article-title":"Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men","volume":"215","author":"DB Hanna","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0237739.ref009","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/infdis\/jis545","article-title":"Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-infection","volume":"206","author":"T Kelesidis","year":"2012","journal-title":"J Infect Dis"},{"key":"pone.0237739.ref010","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jir520","article-title":"Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients","volume":"204","author":"TH Burdo","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0237739.ref011","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","article-title":"Immunologic biomarkers, morbidity and mortality in treated HIV infection","volume":"214","author":"PW Hunt","year":"2016","journal-title":"J Infect Dis"},{"key":"pone.0237739.ref012","doi-asserted-by":"crossref","first-page":"891","DOI":"10.14740\/jocmr3154w","article-title":"C-Reactive protein as an independent cardiovascular risk predictor in HIV+ patients: a focused review of published studies.","volume":"9","author":"TS Gilotra","year":"2017","journal-title":"J Clin Med Res"},{"key":"pone.0237739.ref013","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"SA Riddler","year":"2003","journal-title":"JAMA"},{"key":"pone.0237739.ref014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","article-title":"Comparative changes of lipid levels in treatment-naive HIV-1-infected adults treated with dolutegravir vs efavirenz, raltegravir and ritonavir-boosted darunavir-based regimens over 48 weeks.","volume":"35","author":"R Quercia","year":"2015","journal-title":"Clin Drug Investig"},{"key":"pone.0237739.ref015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1468-1293.2005.00273.x","article-title":"Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort.","volume":"6","author":"WM El-Sadr","year":"2005","journal-title":"HIV Medicine."},{"key":"pone.0237739.ref016","first-page":"1423","article-title":"The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B","volume":"76","author":"KR Feingold","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0237739.ref017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2012.09.010","article-title":"Small dense LDL: An emerging risk factor for cardiovascular disease","volume":"414","author":"S Hirayama","year":"2012","journal-title":"Clin Chim Acta"},{"key":"pone.0237739.ref018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/QAI.0b013e31824476e1","article-title":"Small dense lipoproteins, Apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.","volume":"60","author":"HC Bucher","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0237739.ref019","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3851\/IMP2065","article-title":"Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients.","volume":"17","author":"R Bittar","year":"2012","journal-title":"Antivir Ther."},{"key":"pone.0237739.ref020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QAI.0b013e31817bbbf0","article-title":"Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study","volume":"48","author":"S Riddler","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0237739.ref021","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1097\/QAD.0b013e32833fcb3b","article-title":"HIV, HAART and lipoprotein particle concentrations in the Women\u2019s Interagency HIV Study","volume":"24","author":"PC Tein","year":"2010","journal-title":"AIDS"},{"key":"pone.0237739.ref022","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2012.08.010","article-title":"LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy","volume":"225","author":"M Saumoy","year":"2012","journal-title":"Atherosclerosis"},{"key":"pone.0237739.ref023","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/jac\/dku501","article-title":"Atherogenic properties of lipoproteins in HIV patients starting atazanavir\/ritonavir or darunavir\/ritonavir: a substudy of the ATADAR randomized study","volume":"70","author":"M Saumoy","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"pone.0237739.ref024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3851\/IMP3093","article-title":"Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and association with common carotid artery intima-media thickness: ACTG 5260s.","volume":"22","author":"T Kelesidis","year":"2017","journal-title":"Antiv Ther."},{"key":"pone.0237739.ref025","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000001238","article-title":"Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection","volume":"30","author":"T Kelesidis","year":"2016","journal-title":"AIDS"},{"key":"pone.0237739.ref026","doi-asserted-by":"crossref","first-page":"e0215620","DOI":"10.1371\/journal.pone.0215620","article-title":"HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study","volume":"14","author":"H Low","year":"2019","journal-title":"PLoS One"},{"key":"pone.0237739.ref027","unstructured":"European AIDS Clinical Society Guidelines. Version 6.1. https:\/\/www.eacsociety.org\/files\/2011_eacsguidelines-v6.0-english_oct.pdf"},{"key":"pone.0237739.ref028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1043-4666(02)91961-7","article-title":"Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum.","volume":"19","author":"G Kenis","year":"2002","journal-title":"Cytokine"},{"key":"pone.0237739.ref029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.amjcard.2012.02.051","article-title":"Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.","volume":"110","author":"JL S\u00e1nchez-Quesada","year":"2012","journal-title":"Am J Cardiol."},{"key":"pone.0237739.ref030","volume-title":"Automatic IMT measurements for carotid ultrasound images. In: Abstracts of the Eighth World Congress on Computational Mechanics","author":"A Vernet","year":"2008"},{"key":"pone.0237739.ref031","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.recesp.2012.04.026","article-title":"Grosor \u00edntima-media carot\u00eddeo en poblaci\u00f3n espa\u00f1ola: valores de referencia y asociaci\u00f3n con los factores de riesgo cardiovascular.","volume":"65","author":"M Grau","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"pone.0237739.ref032","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host","volume":"45","author":"W Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"pone.0237739.ref033","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11904-016-0321-0","article-title":"Lipid abnormalities and inflammation in HIV infection","volume":"13","author":"NT Funderburg","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"pone.0237739.ref034","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0000000000000566","article-title":"Oxidized LDL levels are increased in HIV infection and may drive monocyte activation.","volume":"69","author":"DA Zidar","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0237739.ref035","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2008.02.003","article-title":"High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection","volume":"201","author":"MM Guimaraes","year":"2008","journal-title":"Atherosclerosis"},{"key":"pone.0237739.ref036","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP2304","article-title":"Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy.","volume":"17","author":"K Kurz","year":"2012","journal-title":"Antiviral Ther"},{"key":"pone.0237739.ref037","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1012592","article-title":"Carotid-wall intima-media thickness and cardiovascular events","volume":"365","author":"JF Polak","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0237739.ref038","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000000762","article-title":"A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness","volume":"29","author":"JH Stein","year":"2015","journal-title":"AIDS"},{"key":"pone.0237739.ref039","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3851\/IMP2651","article-title":"Rate and predictors of carotid artery intima media thickness progression in antiretroviral-na\u00efve HIV-infected and uninfected adults: a 48-week matched prospective cohort study.","volume":"18","author":"CO Hileman","year":"2013","journal-title":"Antiviral Ther."},{"key":"pone.0237739.ref040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.atherosclerosis.2017.05.004","article-title":"Cardiovascular risk in advanced na\u00efve HIV-infected patients starting antiretroviral therapy: comparison of three different regimens. PREVALEAT II cohort","volume":"263","author":"P Maggi","year":"2017","journal-title":"Atherosclerosis"},{"key":"pone.0237739.ref041","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/23744235.2019.1707279","article-title":"No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide\/emtricitabine plus raltegravir, dolutegravir or elvitegravir\/cobicistat during a two-year follow-up.","volume":"52","author":"L Calza","year":"2020","journal-title":"Infect Dis."},{"key":"pone.0237739.ref042","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2018.12.026","article-title":"Burden of subclinical carotid atherosclerosis and vascular risk factors among people living with HIV in Ghana","volume":"397","author":"FS Sarfo","year":"2019","journal-title":"J Neurol Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T05:07:21Z","timestamp":1667970441000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237739"}},"subtitle":[],"editor":[{"given":"Eliseo A.","family":"Eugenin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0237739","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}